SPHK2 and metabolic dysfunction-associated steatotic liver disease: Meanwhile, SphK2 deficiency inhibited hepatocyte proliferation under a high-fat condition both in vivo and in vitro (Figs. 2H and 3), which demonstrates another layer of its anti-NAFLD-HCC effects at the cellular level.